Search Login Register

Selegiline (E250) Summary

Description: A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.

Also Known As: E250; Jumex; E 250; Deprenyl; E-250 Show All >>

Networked: 862 relevant articles (93 outcomes, 214 trials/studies) for this Drug

Key Diseases for which Selegiline is Relevant

  1. Parkinson Disease (Parkinson's Disease) : 39 outcomes 94 studies in 457 results
  2. Alzheimer Disease (Alzheimer's Disease) : 14 outcomes 17 studies in 81 results
  3. Parkinsonian Disorders (Parkinsonism) : 6 outcomes 34 studies in 84 results
  4. Major Depressive Disorder (Major Depressive Disorders) : 5 outcomes 9 studies in 22 results
  5. Neurodegenerative Diseases (Neurodegenerative Disease) : 5 outcomes 4 studies in 38 results
Show All >>

Drugs Related to Selegiline

  1. Monoamine Oxidase (MAO)
  2. Selegiline (E250)
  3. Levodopa (L Dopa)
  4. rasagiline (Azilect)
  5. Vitamin E
  6. 1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
  7. Bromocriptine (Parlodel)
  8. Tablets
  9. Norepinephrine (Noradrenaline)
  10. levodopa drug combination carbidopa (Nakom)
Show All >>

Therapies Related to Selegiline

  1. Activities of Daily Living (ADL)
  2. Hormone Replacement Therapy (Therapy, Hormone Replacement)
  3. Sympathectomy (Sympathectomies)
  4. Drug Therapy (Chemotherapy)
  5. Injections
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.